and principal investigator of the study “People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily.

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions. Dupilumab is ...

reddening of the skin and painful lesions. The companies noted that the ADEPT trial met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe Bullous pemphigoid who ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters, in some cases ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid ... characterized by blisters, lesions, and skin reddening ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... and rashes to form on the skin. These lesions are prone to infection as they ...

The differential diagnosis includes other diseases that can result in cutaneous and mucous membrane lesions. Vesiculo-bullous diseases such as pemphigus vulgaris, erosive lichen planus ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S ... reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE ...

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin and painful lesions. “People with ...